Dynavax Technologies Corp (DVAX)

[pistol1p]

I see no reason to expect that Heplisav will not get approved by Sept. 15, 2016.

Of course there was not good reason it was not approved the last time it came before the FDA.

When asked about the potential market share that a Dynavax vaccine could achieve, Dr. Balagopal, assistant professor of medicine at the Johns Hopkins University School of Medicine, said that the size of the market likely wouldn’t change much, but Dynavax could potentially take over the vast majority of the current market.

Current Worldwide market for Hep B Vaccines: $1 Billion

Current price: $21.50

DVAX pps should move up substantially in the next six months.